---
title: "Goldline Pharmaceutical Ltd (544759) — Share Price, Financials & Analysis"
symbol: "544759"
company: "Goldline Pharmaceutical Ltd"
canonical: "https://tapetide.com/stocks/544759"
bse_code: "544759"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:58:48.327Z"
---

# Goldline Pharmaceutical Ltd (544759)

Canonical page: https://tapetide.com/stocks/544759

## Company

- **BSE Code:** 544759
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** goldlinepharma.in

## About

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]

## Latest Price

## Key Insights

### Strengths

- Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%

### Weaknesses

- Company has high debtors of 189 days.

## Growth Rates

| Metric | 1Y | 3Y |
| --- | --- | --- |
| net income growth | 42% | 119% |
| revenue growth | 11% | 16% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2025 | Mar 2026 |
| --- | --- | --- |
| Sales | 13.89 | 17.31 |
| Expenses | 11.25 | 13 |
| Operating Profit | 2.64 | 4.31 |
| OPM % | 19.01 | 24.9 |
| Other Income | 0 | 0 |
| Interest | 0.67 | 0.65 |
| Depreciation | 0.12 | 0.12 |
| Profit before tax | 1.85 | 3.54 |
| Tax % | 26.49 | 21.75 |
| Net Profit | 1.36 | 2.76 |
| EPS in Rs | 1.97 | 4 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 19.73 | 23.48 | 28.01 | 31.18 |
| Expenses | 17.32 | 19.14 | 21.86 | 24.09 |
| Operating Profit | 2.41 | 4.34 | 6.15 | 7.09 |
| OPM % | 12.21 | 18.48 | 21.96 | 22.74 |
| Other Income | -0.2 | -0.04 | -0.09 | 0 |
| Interest | 1.63 | 1.61 | 1.95 | 1.46 |
| Depreciation | 0.18 | 0.16 | 0.25 | 0.24 |
| Profit before tax | 0.4 | 2.53 | 3.86 | 5.39 |
| Tax % | 37.5 | 28.46 | 26.42 | 23.38 |
| Net Profit | 0.26 | 1.81 | 2.83 | 4.12 |
| EPS in Rs | 1.3 | 7.87 | 4.1 | 5.97 |
| Dividend Payout % | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 2 | 2.3 | 6.9 | 6.9 |
| Reserves | 2.08 | 3.76 | 1.55 | 5.54 |
| Borrowings | 12.64 | 12.94 | 12.85 | 10.97 |
| Other Liabilities | 2.67 | 3.93 | 4.88 | 5.47 |
| Total Liabilities | 19.39 | 22.93 | 26.18 | 28.88 |
| Fixed Assets | 2.5 | 2.95 | 2.89 | 2.71 |
| CWIP | 0 | 0.45 | 0 | 0 |
| Investments | 0.07 | 0.03 | 0.03 | 0.03 |
| Other Assets | 16.82 | 19.5 | 23.26 | 26.14 |
| Total Assets | 19.39 | 22.93 | 26.18 | 28.88 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | 2.39 | 2.92 | 3.18 | 2.81 |
| Cash from Investing Activity | -1.04 | -1.11 | 0.16 | -0.06 |
| Cash from Financing Activity | -1.44 | -1.08 | -2.89 | -3.4 |
| Net Cash Flow | -0.09 | 0.74 | 0.45 | -0.65 |
| Free Cash Flow | 1.38 | 1.81 | 3.35 | 2.75 |
| CFO/OP | 101 | 72 | 66 | 53 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 159.65 | 149.54 | 139.3 | 188.82 |
| Inventory Days | 336.2 | 450.39 | 229.14 | 202.38 |
| Days Payable | 54.47 | 98.62 | 69.62 | 60.29 |
| Cash Conversion Cycle | 441.39 | 501.32 | 298.82 | 330.91 |
| Working Capital Days | 143.74 | 132.76 | 133.57 | 156.28 |
| ROCE % | — | 23.4 | 29.28 | 30.64 |

## Shareholding Pattern

### annual

| Category | May 2026 |
| --- | --- |
| Promoters | 57.29% |
| FIIs | 5.16% |
| DIIs | 7.81% |
| Public | 29.74% |
| No. of Shareholders | 271 |

### Quarterly

| Category | May 2026 |
| --- | --- |
| Promoters | 57.29% |
| FIIs | 5.16% |
| DIIs | 7.81% |
| Public | 29.74% |
| No. of Shareholders | 271 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 1 / 10 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 38.85 | Sell |
| EMA (10) | 38.29 | Sell |
| SMA (20) | 39.52 | Sell |
| EMA (20) | 39.11 | Sell |
| SMA (50) | 40.26 | Sell |
| EMA (50) | 40.93 | Sell |
| SMA (100) | — | Neutral |
| EMA (100) | — | Neutral |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 36.8 | Neutral |
| MACD (12,26,9) | -0.93 | Sell |
| Stochastic (14,3,3) | 39.62 | Neutral |
| ADX (14) | 20.37 | Neutral |
| Williams %R (14) | -65.75 | Neutral |
| ATR (14) | 1.72 | High Volatility |
| ROC (12) | -6.17 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 58.3 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Aug - Notice published by way of an advertisement in respect of 22nd Annual General Meeting (AGM) of the Company. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug - Notice published by way of an advertisement in respect of 22nd Annual General Meeting (AGM) of the Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3df7bec-8363-44ab-8962-486a61acb66b.pdf) |
| 6 Aug - Goldline Pharmaceutical submitted FY2025-26 annual report; AGM on 29 Aug 2026, with dividend and related-party approvals. | [Reg. 34 (1) Annual Report. 6 Aug - Goldline Pharmaceutical submitted FY2025-26 annual report; AGM on 29 Aug 2026, with dividend and related-party approvals.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fd7521b-4b73-4a18-adbb-4f2bb5d32ba5.pdf) |
| 6 Aug - 22nd AGM on 29 Aug 2026 to adopt FY26 accounts, declare preference dividend, and approve 200 Cr borrowing resolutions. | [Intimation Of Notice Of 22Nd Annual General Meeting Of Goldline Pharmaceutical Limited Will Be Held On Saturday, 29Th August, 2026 At 4:00 P.M. At Hotel Airport Centre Point, 131/1, Adjacent To Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025 6 Aug - 22nd AGM on 29 Aug 2026 to adopt FY26 accounts, declare preference dividend, and approve 200 Cr borrowing resolutions.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b23f5c7d-8bb9-4c17-887e-68161d9d1f2e.pdf) |
| 29 Aug - Promoter Swapan Khandelwal acquired 78,000 shares, 0.81%, via open market on 28 August 2026. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 Aug - Promoter Swapan Khandelwal acquired 78,000 shares, 0.81%, via open market on 28 August 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5F29FC99_0E81_44E1_A399_30B74A14542B_170251.pdf) |
| — | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2 Sep](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6E9F6F28_0A9A_4A6C_A18C_CAFFE86C6A36_110951.pdf) |
| — | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2 Sep](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=E5E3FED7_C90E_469E_84AF_4D96362BF8FE_111210.pdf) |
| — | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1 Sep](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=CC09DD57_CCC2_4F19_9207_E29A5238A294_131127.pdf) |
| — | [Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 31 Aug](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ba4a2c5-39d3-471b-b37c-287edd2a434e.pdf) |
| — | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 Aug](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3626A079_E87F_4B1A_B859_82B5ADF3BC70_170355.pdf) |
| — | [Shareholder Meeting / Postal Ballot-Outcome of AGM 29 Aug](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d2b1b88-99d3-4b5a-9bd5-4bf597d50b2a.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6fd7521b-4b73-4a18-adbb-4f2bb5d32ba5.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:58:48.327Z.